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Inflammatory bowel diseases (IBDs), mainly represented by ulcerative colitis and Crohn’s 
disease, are chronic and idiopathic diseases of the digestive tract. They incidence and 
prevalence is raising significantly in both developed and developing countries, thus 
representing a major challenge for the worldwide healthcare systems. The pharmacological 
armamentarium for the treatment of IBDs is far from being satisfactory, as the therapeutic 
success of the available drugs is still limited. Accordingly, the development of novel and 
effective compounds is highly requested. In this context, the serine/threonine heterotrimeric 
kinase AMPK (adenosine monophosphate-activated protein kinase) seems a sound target to 
strike. 
Known as the central hub of energy homeostasis in eukaryotic cells, AMPK contributes also 
to the modulation of immune/inflammatory cell functions. Actually, alterations in AMPK 
expression and/or activity play a key role in the pathophysiology of immune-mediated 
inflammatory diseases characterized by abnormal immune cell functions, like IBDs. 
Moreover, AMPK is able to improve intestinal health by enhancing para-cellular junctions, 
nutrient transporters, autophagy and apoptosis. Accordingly, AMPK activation represents a 
promising therapeutic strategy for the treatment of intestinal inflammatory disorders.1 
Here we describe a novel heterocyclic derivative, developed as AMPK activator.2 
Tested in C2C12 myoblast cell lines, our compound significantly increased AMPK activity, 
in a concentration-dependent manner, turning out to be more effective than the well-known 
activator acadesine (ACA). Moreover, assayed in a mouse model of acute DNBS-induced 
colitis, the novel heterocycle displayed a relevant anti-inflammatory efficacy, proving to 
ameliorate both systemic- and tissue-related inflammatory parameters like body and spleen 
weight, colon length, macroscopic damage, TNF and MDA levels. Also in this case, our 
compound turned out to be significantly more active that the known reference ACA, thus 
imposing itself as a novel and valuable drug candidate for the treatment of IBDs. 
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